Does adding immunotherapy to neoadjuvant chemotherapy increase postoperative morbidity in gastroesophageal junction adenocarcinoma? A propensity score-matched study - Quiz - MDSpire

Does adding immunotherapy to neoadjuvant chemotherapy increase postoperative morbidity in gastroesophageal junction adenocarcinoma? A propensity score-matched study

  • By

  • Huiliang Zhang

  • Qingwen Huang

  • Jitao Du

  • Xiangbin Wan

  • July 3, 2026

  • 0 min

Share

Original Source(s)

Does adding immunotherapy to neoadjuvant chemotherapy increase postoperative morbidity in gastroesophageal junction adenocarcinoma? A propensity score-matched study

  • by Huiliang Zhang, Qingwen Huang, Jitao Du, Xiangbin Wan

  • July 3, 2026

Related Content

Physicians’ attitudes and perceptions toward the integration of artificial intelligence into pediatric hematology–oncology in Saudi Arabia

Case report: Secretory carcinoma of the breast with ETV6-NTRK3 fusion: clinicopathological features and molecular confirmation by FISH in two cases

Prediction of histological grading in ductal carcinoma in situ based on mammographic signs and clinical information using machine learning models